Two-year follow-up of patients with Atrial Fibrillation receiving Edoxaban in routine clinical practice : results from the global ETNA-AF program
De Caterina, Raffaele Unverdorben, Martin Chen, Cathy Choi, Eue-Keun Koretsune, Yukihiro Morrone, Doralisa Pecen, Ladislav Bramlage, Peter Wang, Chun-Chieh Yamashita, Takeshi
De Caterina, Raffaele
Unverdorben, Martin
Chen, Cathy
Choi, Eue-Keun
Koretsune, Yukihiro
Morrone, Doralisa
Pecen, Ladislav
Bramlage, Peter
Wang, Chun-Chieh
Yamashita, Takeshi
Citations
Altmetric:
Affiliation
Pisa University Hospital; Fondazione Villa Serena per la Ricerca; Daiichi Sankyo, Inc; Sandwell and West Birmingham NHS Trust; et al.
Other Contributors
Publication date
2025-02
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Randomized clinical trials demonstrated similar efficacy and improved safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation (AF). Long-term data in routine clinical practice are needed. Hypothesis: Patients with AF receiving edoxaban at baseline continue to have low annualized effectiveness and safety event rates in the second year of follow-up, with regional variations observed. Methods: The Global ETNA-AF program is a prospective, noninterventional study of patients with AF receiving edoxaban. Patient characteristics and annualized clinical event rates were assessed overall and by region across the 2-year follow-up. Annualized event rates of bleeding and thromboembolic events were assessed within the first year and conditionally in patients who were event-free up to 12 months in the second year. Results: This analysis comprised 26 805 patients from Europe (n = 13 164), Japan (n = 10 342), and non-Japanese Asian regions (n = 3299). Patients from Europe had the highest burden of comorbidities. The annualized event rates for major bleeding, any stroke, all-cause death, and cardiovascular death varied by region. The global annualized event rates in the first and second year were 1.31%/year and 0.86%/year for major bleeding, 1.06%/year and 0.65%/year for any stroke, 0.84%/year and 0.73%/year for cardiovascular death, and 3.05%/year and 3.18%/year for all-cause death. Conclusion: Annualized event rates for any stroke and major bleeding remained low through 2-year follow-up for patients with AF receiving edoxaban at baseline. Differences in annualized event rates for all-cause and cardiovascular mortality between Europe, Japan, and non-Japanese Asian regions may reflect variations in baseline characteristics. Trial registration: Europe, NCT02944019; Japan, UMIN000017011; Korea/Taiwan, NCT02951039; Hong Kong, NCT03247582; and Thailand, NCT03247569.
Citation
De Caterina R, Unverdorben M, Chen C, Choi EK, Koretsune Y, Morrone D, Pecen L, Bramlage P, Wang CC, Yamashita T, Kirchhof P. Two-Year Follow-Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA-AF Program. Clin Cardiol. 2025 Feb;48(3):e70091. doi: 10.1002/clc.70091
Type
Article